Cargando…

Clinical enrollment assay to detect preexisting neutralizing antibodies to AAV6 with demonstrated transgene expression in gene therapy trials

Recombinant adeno-associated virus (AAV) vectors are the leading platform for gene delivery for a variety of clinical applications. Patients with preexisting antibodies to AAV are currently excluded from most AAV gene therapy trials to avoid vector neutralization and ensure response to therapy. Anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Liching, Ledeboer, Annemarie, Pan, Yonghua, Lu, Yanmei, Meyer, Kathleen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935387/ https://www.ncbi.nlm.nih.gov/pubmed/35778500 http://dx.doi.org/10.1038/s41434-022-00353-2

Ejemplares similares

A sensitive AAV transduction inhibition assay assists evaluation of critical factors for detection and concordance of pre-existing antibodies
por: Pan, Yonghua, et al.
Publicado: (2023)

AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction
por: Yasuda, Makiko, et al.
Publicado: (2020)

Rapid AAV-Neutralizing Antibody Determination with a Cell-Binding Assay
por: Guo, Ping, et al.
Publicado: (2018)

IL12-Mediated Liver Inflammation Reduces the Formation of AAV Transcriptionally Active Forms but Has No Effect over Preexisting AAV Transgene Expression
por: Gil-Fariña, Irene, et al.
Publicado: (2013)

Oracle or false prophet? Can we predict AAV efficacy based on preexisting antibody titers?
por: Anguela, Xavier M., et al.
Publicado: (2019)

Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations
por: Mendell, Jerry R., et al.
Publicado: (2022)

High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes
por: Gardner, Matthew R., et al.
Publicado: (2022)

Confirmatory detection of neutralizing antibodies to AAV gene therapy using a cell-based transduction inhibition assay
por: Kasprzyk, Theresa, et al.
Publicado: (2022)

Global CNS Gene Delivery and Evasion of Anti-AAV Neutralizing Antibodies by Intrathecal AAV Administration in Non-Human Primates
por: Gray, Steven J., et al.
Publicado: (2013)

Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity
por: Pei, Xiaolei, et al.
Publicado: (2020)

Multiplexing AAV Serotype-Specific Neutralizing Antibodies in Preclinical Animal Models and Humans
por: Kuoch, Hisae, et al.
Publicado: (2023)

A Novel High-Throughput Vaccinia Virus Neutralization Assay and Preexisting Immunity in Populations from Different Geographic Regions in China
por: Liu, Qiang, et al.
Publicado: (2012)

Preexisting Japanese Encephalitis Virus Neutralizing Antibodies and Increased Symptomatic Dengue Illness in a School-Based Cohort in Thailand
por: Anderson, Kathryn B., et al.
Publicado: (2011)

Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction
por: Fitzpatrick, Zachary, et al.
Publicado: (2018)

Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme
por: Elmore, Zachary C., et al.
Publicado: (2020)

rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis
por: Derkaev, Artem A., et al.
Publicado: (2022)

Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies
por: Gardner, Matthew R., et al.
Publicado: (2019)

Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates
por: Samelson-Jones, Benjamin J., et al.
Publicado: (2020)

Design of antibody variable fragments with reduced reactivity to preexisting anti-drug antibodies
por: Johansson, Maria U., et al.
Publicado: (2023)

Selection of an Efficient AAV Vector for Robust CNS Transgene Expression
por: Hanlon, Killian S., et al.
Publicado: (2019)

Durability of transgene expression after rAAV gene therapy
por: Muhuri, Manish, et al.
Publicado: (2022)

RNAi-mediated rheostat for dynamic control of AAV-delivered transgenes
por: Subramanian, Megha, et al.
Publicado: (2023)

Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington’s disease
por: Hadaczek, Piotr, et al.
Publicado: (2016)

Optimized AAV rh.10 Vectors That Partially Evade Neutralizing Antibodies during Hepatic Gene Transfer
por: Selot, Ruchita, et al.
Publicado: (2017)

Tetramer-Based Enrichment of Preexisting Anti-AAV8 CD8(+) T Cells in Human Donors Allows the Detection of a T(EMRA) Subpopulation
por: Vandamme, Céline, et al.
Publicado: (2020)

Preexisting prediabetes and the severity of COVID-19
por: Sathish, Thirunavukkarasu, et al.
Publicado: (2021)

An Attempt to Demonstrate Neutralizing Antibodies to the Mammary Tumour “Milk Agent” in Mice
por: Gorer, P. A., et al.
Publicado: (1949)

Preexisting Antibodies to an F(ab′)(2) Antibody Therapeutic and Novel Method for Immunogenicity Assessment
por: Ruppel, Jane, et al.
Publicado: (2016)

Lung-Targeted Transgene Expression of Nanocomplexed Ad5 Enhances Immune Response in the Presence of Preexisting Immunity
por: Yang, Yilong, et al.
Publicado: (2023)

A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies
por: Fournier, Carole, et al.
Publicado: (2007)

Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions
por: Weber, Thomas
Publicado: (2021)

AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity
por: Fuchs, Sebastian P., et al.
Publicado: (2015)

Enhanced sensitivity of neutralizing antibody detection for different AAV serotypes using HeLa cells with overexpressed AAVR
por: Zheng, Zhaoyue, et al.
Publicado: (2023)

Medicare Preferred Provider Organization Demonstration: Plan Offerings and Beneficiary Enrollment
por: Pope, Gregory C., et al.
Publicado: (2006)

Adenovirus‐associated antibodies in UK cohort of hemophilia patients: A seroprevalence study of the presence of adenovirus‐associated virus vector–serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A
por: Stanford, Sophia, et al.
Publicado: (2019)

MSD-based assays facilitate a rapid and quantitative serostatus profiling for the presence of anti-AAV antibodies
por: Haar, Janina, et al.
Publicado: (2022)

Engineering passive immunity in transgenic mice secreting virus-neutralizing antibodies in milk
por: Castilla, Joaquin, et al.
Publicado: (1998)

Successful Transduction with AAV Vectors after Selective Depletion of Anti-AAV Antibodies by Immunoadsorption
por: Orlowski, Alejandro, et al.
Publicado: (2020)

AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region
por: van den Berg, Fiona T., et al.
Publicado: (2019)

Immunosuppression reduces rAAV2.5T neutralizing antibodies that limit efficacy following repeat dosing to ferret lungs
por: Tang, Yinghua, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9qu1u0ik0nbi6p1srjbt3do41p